

**Date:** 27<sup>th</sup> May, 2026

To,  
Corporate Services Department,  
**BSE Limited**,  
Phiroze Jeejeebhoy Towers,  
1st Floor, Dalal Street,  
Fort, Mumbai - 400001.

**Scrip Code:** 540204

**Subject:** Newspaper Publication of Financial Results for the Quarter and Year ended 31<sup>st</sup> March, 2026.

Dear Sir/ Madam,

Pursuant to Regulations 30 and 47 read with Schedule III of SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, please find enclosed a copy of newspaper publication in the following newspapers dated 27<sup>th</sup> May, 2026 with respect to Audited Financial Results (Standalone & Consolidated) of the Company for the Quarter and Year ended 31<sup>st</sup> March, 2026 approved at the meeting of Board of Directors held on Tuesday, 26<sup>th</sup> May, 2026.

1. Mumbai Lakshadeep (Marathi)
2. Financial Express (English)

Copy of the results are also uploaded on the website of our Company - [www.eikolifesciences.com](http://www.eikolifesciences.com).

Kindly take the same on your records.

Thanking you,  
Yours sincerely.

**For Eiko Lifesciences Limited**

**Chintan Doshi**  
**Compliance officer & Company Secretary**  
**Membership No: A36190**  
**Encl: as above**





(CIN: L65993MH1977PLC258134)

Regd off: 604, Centrum, Opp. TMC Office, Near Satkar Grand Hotel, Wagale Estate, Thane West MH 400604.  
E-mail: investor.relations@eikolifesciences.com Tel. No.: +91902698959 Website: www.eikolifesciences.com

**EXTRACT OF AUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND YEAR ENDED 31-03-2026**

Sr. No.	Particulars	Standalone						Consolidated					
		Quarter Ended		Year Ended		Quarter Ended		Year Ended					
		31-03-2026	31-12-2025	31-03-2025	31-03-2026	31-03-2025	31-03-2026	31-12-2025	31-03-2025	31-03-2026	31-03-2025		
		(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)		
1	Total Income from Operations	1635.79	1,013.01	761.79	4425.61	3,351.58	1,846.93	1,230.07	1,150.03	5,367.94	3,838.02		
2	Net profit/ (Loss) for the period before tax (before Exceptional and/ or extraordinary items)	149.33	124.39	85.46	471.30	197.69	204.76	187.13	122.54	706.47	258.04		
3	Net profit/ (Loss) for the period before tax (After Exceptional and/ or extraordinary items)	149.33	124.39	119.59	471.30	231.82	204.76	187.13	156.66	706.47	292.16		
4	Net profit/ (Loss) for the period after tax (After Exceptional and/ or extraordinary items)	112.39	94.74	90.10	358.11	174.08	152.60	139.46	117.33	527.17	217.53		
5	Net profit after taxes and share of profit of Associates	112.39	94.74	90.10	358.11	174.08	149.72	142.55	124.36	532.47	231.86		
6	Total comprehensive Income for the period [Comprising Profit/ (Loss) for the period (after tax), share of profit of Associates and Other Comprehensive Income (after tax)]	112.39	94.74	90.10	358.11	174.08	149.72	142.55	124.36	532.47	231.86		
7	Paid up equity share Capital	1,434.59	1,372.09	1,376.27	1,434.59	1,376.27	1,434.59	1,372.09	1,376.27	1,434.59	1,287.28		
8	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance sheet of the previous year.	-	-	-	4909.65	4,266.10	-	-	-	5,037.66	4,302.58		
9	Basic Earning Per Share (Not Annualised) (EPS in ₹)	0.80	0.69	0.69	2.60	1.34	0.93	0.88	0.80	3.26	1.62		
9	Diluted Earning Per Share (Not Annualised) (EPS in ₹)	0.74	0.69	0.69	2.54	1.34	0.86	0.88	0.80	3.19	1.62		

**Notes:**

- The above Audited Standalone and Consolidated Financial Results for the quarter and year ended 31st March, 2026 were reviewed by the Audit committee of the Board on 26th May, 2026 and thereafter approved by the board of directors of the company at their meeting held on 26th May, 2026. The Audit Report issued by Statutory Auditor has no qualification / modification.
- These Financial Results have been prepared in accordance with Indian Accounting Standards ("Ind AS") notified under Section 133 of the Companies Act 2013 read with the Companies (Indian Accounting Standards) Rules, 2015 (as amended)
- The impact on net profit / loss, total comprehensive income or any other relevant financial item(s) due to change(s) in accounting policies shall be disclosed by means of a footnote of financials.
- The above is an extract of the details format of Quarter and Year Ended Results filed with the stock exchange under Regulation 33 of SEBI (listing Obligations and Disclosure Requirements) Regulation, 2015. The full format of the Quarter and Year ended Financial Results are available on stock exchange website at [www.bseindia.com](http://www.bseindia.com) and also on the company's website i.e., [www.eikolifesciences.com](http://www.eikolifesciences.com).
- The Company's Consolidated financial Results include financial results of:
  - Eiko Scientific Solutions LLP - Wholly Owned Subsidiary
  - Eikovivify Logistics Private Limited - Subsidiary
  - Reflux Pharmaceuticals Private Limited - Associate Company
  - SSM Formulations Private Limited - Associate Company

For, EIKO LIFESCIENCES LIMITED  
Sd/-  
Chintan Doshi  
Company Secretary & Compliance Officer  
AS3190

Date: 26-05-2026  
Place: Thane

